Search result from the Trials Tracker
This trial has been archived
Study details
To evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and VX-561 (deuterated ivacaftor, also known as CTP-656) in subjects with cystic fibrosis (CF)who are homozygous for the F508del mutation (F/F)
Study results summary
These results suggest Kaftrio could be a more effective treatment than tezacaftor plus ivacaftor alone for people with cystic fibrosis with two copies of the F508del mutation.
- Trials Tracker ID
- TT001876
- Age range
- 12 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Study details
This study is designed to evaluate the effectiveness and safety of lenabasum (JBT-101) in people with CF who have had pulmonary exacerbations. Lenabasum (JBT-101) is an oral medication that is aimed at reducing inflammation. It is thought to help the body increase production of anti-inflammatory molecules while reducing production of molecules that increase inflammation. Reduction of inflammation helps prevent permanent tissue damage in the lungs that happens when CF patients have pulmonary exacerbations. For study participants this study includes 6 months of study treatment with a 1 month follow up period. Study participants may remain on their current CF treatments
- Trials Tracker ID
- TT001871
- Age range
- 12 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Anti-Inflammatory
Search result from the Trials Tracker
This trial has been archived
Study details
Cystic fibrosis affects the digestive system and leads to a number of unpleasant symptoms. Those relating to the bowels are often overlooked and can be hard to treat. We are hoping to evaluate a new questionnaire –the CF bowel score (CF-BS)–specifically designed to look at CF bowel disease. We hope it will improve identification and allow us to measure response to treatment. The patient will complete the CF-BS at their routine clinic appointment along with providing relevant clinical information. One group of patients will be sent home with the CF-BS to complete at home and return to us within a...
- Trials Tracker ID
- TT001866
- Age range
- 18 years and older
- Length of participation
- 1 week
- Trial status
- Closed with results
- Therapeutic approach
- Other
Search result from the Trials Tracker
This trial has been archived
Study details
A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
- Trials Tracker ID
- TT001861
- Age range
- 12 years and older
- Length of participation
- 24 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
This trial has been archived
Study details
Gastro - oesophageal reflux disease(GORD) is a condition where acid from the stomach leaks out of the stomach and up into the oesophagus (gullet) It is common in patient with Cystic Fibrosis. Although symptoms such as heartburn and acid taste in the mouth can occur, often there are no symptoms. Studies have suggested a link between a worsening lung function and the amount of GORD. A potential mechanism is by the stomach content travelling into the lungs causing inflammation and altering the usual organisms that are present. If that is the case, there may be opportunities for new drugs and...
- Trials Tracker ID
- TT001856
- Age range
- 18+
- Length of participation
- 24 hours
- Trial status
- Closed with results
- Therapeutic approach
- Other
Search result from the Trials Tracker
Study details
This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation
- Trials Tracker ID
- TT001851
- Age range
- Aged under 2 years
- Length of participation
- 104 weeks
- Trial status
- Recruitment complete
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Study details
This is a Phase Ib, multi-center, open-label, nonrandomized multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of a combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in adult subjects with Cystic Fibrosis.
- Trials Tracker ID
- TT001846
- Age range
- 18+
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
This trial has been archived
Study details
The single treatment group will enroll adult subjects with CF currently on stable KALYDECO® background therapy for a minimum of 3 months at the time of randomization. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 14 Days. The subjects will continue treatment with KALYDECO® throughout the study.
- Trials Tracker ID
- TT001826
- Age range
- 18+
- Length of participation
- 21 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Study details
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease. There are six different potential dosing regimens, including one that is placebo.
- Trials Tracker ID
- TT001821
- Age range
- 18+
- Length of participation
- 3 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Mucociliary Clearance
